Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

ooking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Omeros' actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros' unproven preclinical and clinical development activities, regulatory oversight, commercialization of its products, intellectual property claims and the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 9, 2013. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.OMEROS CORPORATIONCONSOLIDATED STATEMENTS OF OPERATIONS(In thousands, except share and per share data)Three Months EndedNine Months EndedSeptember 30,September 30,2013201220132012(unaudited)(unaudited)Revenue

$
96

$
,417

$
,431

$
4,439Operating expenses:Research and development

9,420

7,764

26,111

22,568Selling, general and administrative

4,210

2,736

11,934

7,270Litigation settlement

-

3,953

-

3,953Total operating expenses

13,630

14,453

38,045

33,791Loss from operations

(13,434)

(13,036)

(36,614)

(29,352)Investment income

2

14

10

32Interest expense

(592)

(413)

(1,768)

(1,360)Other income, (expense) net

154

159

421

(30)Net loss

$
(13,870)


SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2014)... 26, 2014 Vycom announced today that ... specializes in chemical process equipment, has selected its Flametec ... Facility for Rare Isotope Beams (FRIB). This involved ... line made with Vycom’s Flametec PVC-C and Kytec PVDF ... essential parts of FRIB’s linear accelerator (known as LINAC). ...
(Date:8/26/2014)... 2014 Trovagene, Inc. (NASDAQ:  TROV) presented ... Moving Assays to the Clinic with an ... Cell Free Tumor DNA in Urine." In this ... Precision Cancer Monitoring (PCM) platform and results from ... detection of tumor DNA mutations from urine samples ...
(Date:8/26/2014)... , Aug. 26, 2014  Guardant Health, a ... of oncology diagnostic products, has been recognized today ... Technology Pioneer . As an innovator in ... 24 companies across a wide variety of industries ... Guardant360 ® , Guardant Health,s first ...
(Date:8/26/2014)... , Aug. 26, 2014 Albany Molecular ... that William S. Marth , President and Chief ... Stanley Global Healthcare Conference on Monday, September 8, 2014 ... audio webcast of the presentation can be accessed at ... The webcast will be archived for 90 ...
Breaking Biology Technology:Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 2Modutek Selects Vycom’s Flametec Materials for Michigan State University’s Superconductor Equipment 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 2Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 3Highly Sensitive and Quantitative Analytical Performance is Translational for Clinical Utility of Cell-Free Tumor DNA Diagnostics 4Guardant Health Named a 2015 Technology Pioneer by World Economic Forum 2
... Company also Initiates the Phase 2b ASTUTE Clinical Trial ... Therapeutics, Inc., a privately held biopharmaceutical company, announced that ... the treatment of patients with low-grade hepatic encephalopathy was ... the European Association for the Study of Liver Disease ...
... palliation as an acceptable primary endpoint, ... WA, April 28 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. (NASDAQ: ... has reached an agreement with the U.S. Food and ... Phase 3 registration trial of OGX-011, its lead product ...
... compliance and persistence with chronic medications. Prescription refills increase up ... free service offers coaching, reminders and pharmacist support to alleviate ... - prescribed medication. , ... ...
Cached Biology Technology:Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 2Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 2OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 3OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 4OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 5OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer 6New Pleio Medication Adherence Service Increases Prescription Refills Up To 53% 2
(Date:8/26/2014)... in St. Louis have developed algorithms to identify weak ... or breaking. The technology, which needs to be refined ... help pinpoint minor strains and tiny injuries in the ... research is available online Aug. 27 in the ... research at the nexus of the physical and life ...
(Date:8/26/2014)... a pen a New Zealand endemic tree has for the ... group of ,weedy, Australian shrubs and small trees. A New ... surprises and discover astonishing cryptic diversity behind what was long ... the open access journal PhytoKeys . , ... was one of the many discoveries made in the north-western ...
(Date:8/26/2014)... -- Unregulated trash burning around the globe is pumping ... official records. A new study led by the National ... percent of the world,s garbage is burned in such ... human health and climate change. , The new study ... of pollutants such as particulates, carbon monoxide, and mercury ...
Breaking Biology News(10 mins):New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 2And then there were 10 -- unexpected diversity in New Zealand kanuka genus Kunzea 3Trash burning worldwide significantly worsens air pollution 2Trash burning worldwide significantly worsens air pollution 3
... Fifty-nine leading life scientists from Europe and around the ... Organization (EMBO) for their proven excellence in research. Fifty-one ... Europe and neighbouring countries, while eight equally respected scientists ... as Associate Members, bringing the current membership total to ...
... herbicide that is effective at killing broadleaf weeds in ... Illinois and other Midwestern states, may finally have a ... developed a new grape called Improved Chancellor which is ... 1946, 2,4-Dichlorophenoxyacetic or 2, 4-D was introduced. It was ...
... is available in Spanish . An ... the Institute for Research in Biomedicine (IRB Barcelona) and ... (ICIQ, Tarragona), have discovered a substance with the capacity ... certain mutations that promote the appearance of cancer. Giralt, ...
Cached Biology News:EMBO honors 59 leading life scientists 2Herbicide-resistant grape could revitalize Midwest wine industry 2Herbicide-resistant grape could revitalize Midwest wine industry 3Design of a compound that stabilizes the main natural suppressor of tumors 2
... Clear yellow solution. In ... thimerosal, and other proprietary ... Diluent formulated to stabilize ... antibody conjugates at high ...
... software is used to predict ... DNA sequence up to 3,200 ... placement of primers and GC ... denaturing gradient gel electrophoresis (DGGE), ...
... The Mini-Sub cell GT cell and PowerPac ... gel electrophoresis of nucleic acids in agarose gels. ... tank, lid with cables and electrodes, a 7 ... ruler, two casting gates, and two 1.5 mm ...
... PowerPac basic power supply are used for submerged ... gels. The mini format cell includes a buffer ... bubble. The PowerPac basic power supply, 100-120 and ... mA, and 75 W. Power cord and instructions ...
Biology Products: